We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Zinc(II)—The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19?
- Authors
Hecel, Aleksandra; Ostrowska, Małgorzata; Stokowa-Sołtys, Kamila; Wątły, Joanna; Dudek, Dorota; Miller, Adriana; Potocki, Sławomir; Matera-Witkiewicz, Agnieszka; Dominguez-Martin, Alicia; Kozłowski, Henryk; Rowińska-Żyrek, Magdalena
- Abstract
Zn(II) is an inhibitor of SARS-CoV-2′s RNA-dependent RNA polymerase, and chloroquine and hydroxychloroquine are Zn(II) ionophores–this statement gives a curious mind a lot to think about. We show results of the first clinical trials on chloroquine (CQ) and hydroxychloroquine (HCQ) in the treatment of COVID-19, as well as earlier reports on the anticoronaviral properties of these two compounds and of Zn(II) itself. Other FDA-approved Zn(II) ionophores are given a decent amount of attention and are thought of as possible COVID-19 therapeutics.
- Subjects
UNITED States. Food &; Drug Administration; COVID-19; CHLOROQUINE; RNA replicase; RNA polymerases; HYDROXYCHLOROQUINE; SARS-CoV-2
- Publication
Pharmaceuticals (14248247), 2020, Vol 13, Issue 9, p228
- ISSN
1424-8247
- Publication type
Article
- DOI
10.3390/ph13090228